期刊文献+

葡萄膜炎合并全身结核病不当应用阿达木单抗治疗2例 被引量:1

Uveitis complicated with systemic tuberculosis associated with inappropriate adalimumab therapy:two case reports
暂未订购
导出
摘要 例1,患者,男,56岁,因咳嗽、发热10 d于2020年5月28日收入江苏省苏北人民医院呼吸科。患者诉3个月前在外院诊断双眼小柳-原田病,先后予以全身糖皮质激素、环孢素、阿达木单抗治疗,但仍反复发作。眼科会诊:最佳矫正视力(best corrected visual acuity,BCVA)右眼0.3,左眼1.0,双眼角膜透明,KP(-),房水闪辉(+),玻璃体轻度混浊,右眼后极部视网膜水肿(图1A),左眼后极部视网膜静脉稍迂曲扩张(图1B)。光相干断层扫描(optical coherence tomography,OCT)结果示双眼视网膜色素上皮(retinal pigment epithelium,RPE)层有高反射物质沉积,右眼黄斑区视网膜浆液性脱离(图1C,D)。荧光素眼底血管造影(fluorescein fundus angiography,FFA)和吲哚菁绿血管造影(indocyanine green angiography,ICGA)检查示双眼多灶性脉络膜炎,双眼视网膜血管炎(图1E,F)。入院后呼吸科检查:T细胞斑点检测(T cell spot test,T-SPOT)阳性;支气管镜活检结果示左主、左上下叶支气管结核(炎症浸润+肉芽增生型),痰结核分枝杆菌DNA(+)。诊断:活动性肺结核,双眼结核相关葡萄膜炎。追问病史,患者首诊原田病使用糖皮质激素治疗前T-SPOT阳性,未处理。患者转传染病医院予以正规抗结核治疗,并停用糖皮质激素、环孢素、阿达木单抗。抗结核治疗后2周复查,双眼BCVA 1.0,右眼前房闪辉(-),OCT提示右眼黄斑区浆液性视网膜脱离已复位(图1G)。患者经正规抗结核治疗后3个月复查,肺部活动性结核病灶稳定,双眼视力1.0,RPE层高反射物质较前减少;1年后停药,随访近1年未复发。
作者 孙露丹 朱婕 朱俊 虞晶 陈放 Sun Ludan;Zhu Jie;Zhu Jun;Yu Jing;Chen Fang(Department of Ophthalmology,Northern Jiangsu People's Hospital of Jiangsn Province,Yangzhou 225001,China)
出处 《中华实验眼科杂志》 CAS CSCD 北大核心 2022年第8期723-724,共2页 Chinese Journal Of Experimental Ophthalmology
基金 2020年扬州市社会发展计划项目(YZ2020112)。
  • 相关文献

二级参考文献22

  • 1刘新,梁瑞霞.异烟肼与利福平联用预防结素强阳性人群发病的观察[J].中原医刊,2004,31(18):55-55. 被引量:3
  • 2Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosi in Quebec, Canada.Arthritis Rheum, 2009, 6t: 300-304.
  • 3Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol, 2007, 34:706-711.
  • 4Carmona L, Hemandez-Gareia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatoh 2003, 30: 1436-1439.
  • 5Gomez-Reino JJ, Cannona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multi- center active-surveillance report. Arthritis Rheum, 2003, 48: 2122-2127.
  • 6Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis, 2006, 43: 717-722.
  • 7Chen DY, Shen GH, Lan JL, et al. Biphasic emergence of ac-tire tuberculosis in rheumatoid arthritis patients receiving TNF-ot inhibitors: the utility of IFN-T assay. Ann Rheum Dis, 2012, 71 : 231-237.
  • 8Singh JA, Furst DE, Bharat A, et 81. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hobo- ken), 2012, 64: 625-639.
  • 9Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum, 2008, 59: 800-806.
  • 10Miyasaka N, Takeuchi T, Eguchi K. Gyidelines for the proper use of etanercept in Japan. Mod Rheumatol, 2006, 16: 63-67.

共引文献60

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部